Advances in our understanding of the mechanisms of tau-mediated neurodegeneration in
Alzheimer's disease (AD) and related tauopathies, which are characterized by prominent …

Insoluble protein aggregates have been linked to Alzheimer's disease (AD) and
frontotemporal dementia (FTD). Recent work in transgenic mice has shed light on the role of …

Alzheimer's disease (AD) is a complex age‐related neurodegenerative disease. In this
review, we carefully detail amyloid‐β metabolism and its role in AD. We also consider the …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in the growing
population of elderly people. A hallmark of AD is the accumulation of plaques in the brain of …

Alzheimer's disease (AD) is a progressive neurodegenerative disease that represents the
most common form of dementia among the elderly. Despite the fact that AD was studied for …

With increasing feasibility of predicting conversion of mild cognitive impairment to dementia
based on biomarker profiling, the urgent need for efficacious disease‐modifying compounds …

Although animal models of Alzheimer's disease (AD) recapitulate β-amyloid-dependent
hippocampal synaptic and cognitive dysfunctions, it is poorly understood how cortex …

The enzymatic activity of butyrylcholinesterase (BChE) in the brain increases with the
progression of Alzheimer's disease, thus classifying BChE as a promising drug target in …

Despite great advances in basic neuroscience knowledge, the improved understanding of
brain functioning has not yet led to the introduction of truly novel pharmacological …

Purpose H102, a novel β-sheet breaker peptide, was encapsulated into liposomes to reduce
its degradation and increase its brain penetration through intranasal administration for the …